

 $\boxtimes$ 

## 180.00 DA

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of FRICK, et al.

Application No.: 10/734,573

Filed: December 12, 2003

Title: NOVEL HETEROCYCLIC

FLUOROGLYCOSIDE DERIVATIVES, MEDICAMENTS CONTAINING

THESE COMPOUNDS AND THE USE

THEREOF

by certify that this correspondence is being ted with the United States Postal Service as First Mail in an envelope addressed to Commissioner tents, P.O. Box 1450, Alexandria, VA 22313-

Not Yet Known

Not Yet Known

Examiner:

Art Unit:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop Patent Application Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

(b)	This	Information Disclosure Statement is filed after the period set forth in 37 C.F.R.
	1.97	(b), but is believed to be filed before the mailing date of a final action under §1.113
	or a	notice of allowance under §1.311, whichever occurs first.
	(1)	The undersigned attorney certifies that each item of information contained in this
		Information Disclosure Statement was cited in a communication from a foreign
		patent office in a counterpart foreign application not more than three months prior
		to the filing of this statement;
	(2)	The undersigned attorney certifies that no item of information contained in this
		Information Disclosure Statement was cited in a communication from a foreign
		patent office in a counterpart foreign application or, to the knowledge of the
		undersigned attorney after making reasonable inquiry, was known to any
		individual designated in §1.56(c) more than three months prior to the filing of this
		statement; or
	(3)	This Information Disclosure Statement is accompanied by a transmittal letter in
		which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is
		authorized.
		D + C-11 1 14 1

Respectfully submitted,

Barbara E. Kurys, Reg. No. 34,650

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2965
Telefax (908) 231-2626

Aventis Docket No. DEAV2002/0087 US NP

Please	tune a	nlue ein	n (+)	inside this	hov	->	
riease	type a	plus sig	m (*)	inside this	UUX	~	

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

Complete if Known					
Application Number	10/734,573				
Filing Date	12-12-2003				
First Named Inventor	FRICK, et al.				
Group Art Unit	Not Yet Known				
Examiner Name	Not Yet Known				
Attorney Docket Number	DEAV2002/0087 - US - NP				

	U.S. PATENT DOCUMENTS							
Examiner Initials*	No.1 Number Kind Code <sup>2</sup>			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		10/151,436		Bristol-Myers Squibb Company	05-20-2002			
		6221633		ERTL	04-24-2001			
		6221897		BARINGHAUS	04-24-2001			
		6245744		BARINGHAUS	06-12-2001			
		6342512		KIRSCH	01-29-2002			
						`		

				FOR	EIGN PATENT DOCUMENT	S		
Examiner Initials*	Cite No.1	Foreign Patent Document  Kind Code <sup>5</sup> Office <sup>3</sup> Number <sup>4</sup> (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6	
		EP	0 462 884		Adir et compagnie	12-27-1991		
		EP	0 850 948		Tanabe Seiyaku Co., Ltd.	07-01-1998		
		DE	10142734		GLOMBIK	03-27-2003		
		JP	2000-80041			03-21-2000		
		wo	00/40569		Alizyme Therapeutics Limited	07-13-2000		
		wo	00/63208		Novo Nordisk A/S - Boehringer	10-26-2000		
		wo	00/64876		,	11-02-2000		
		wo	00/64888			11-02-2000		
		wo	00/66585		Neurogen Corporation	11-09-2000		
		wo	00/71549		Knoll Aktiengesellschaft	11-30-2000		

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box ->	Approved for use the
	Approved for use us

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO 10/734,573 **Application Number** INFORMATION DISCLOSURE Filing Date 12-12-2003 STATEMENT BY APPLICANT First Named Inventor FRICK, et al. Not Yet Known Group Art Unit (use as many sheets as necessary) Examiner Name Not Yet Known Attorney Docket Number DEAV2002/0087 - US - NP 2 of 5 Sheet

				U.S. PATENT DOC	JMENTS	
Examiner Initials	Cite No.1	U.S. Paten	Kind Code <sup>2</sup>	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
				<del></del>		

				FOR	EIGN PATENT DOCUMENT	S		
Examiner Initials*	Cite No.1	Kind Code		Cument Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Te
		wo	00/78312		Merck & Co., Inc.	12-28-2000		
		wo	01/09111		Eli Lilly and Company	02-08-2001		
		wo	01/16147 ·		Kissei Pharmaceutical Co., Ltd	03-08-2001		
		wo	01/27128		Bristol-Myers Squibb Company	04-19-2001		
		wo	01/68660		Kissei Pharmaceuticals Co., Lt	09-20-2001		
		wo	01/74834		Bristol-Myers Squibb Company	10-11-2001		
		wo	01/74835		Bristol-Myers Squibb Company	10-11-2001		
		wo	01/83451		Asahi Kasei Kabushiki Kaisha	11-08-2001		
		wo	01/85695		Bristol-Myers Squibb Co.	11-15-2001		
		wo	01/91752		Merck & Co., Inc.	12-06-2001		

Examiner	Date	
Signature	Considered	

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box	→	П
---	---	---

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitu	ite for form 1449A/PT	0		Complete if Known		
				Application Number	10/734,573	
INF	ORMATION	1 DI	SCLOSURE	Filing Date	12-12-2003	
STA	TEMENT E	BY A	APPLICANT	First Named Inventor	FRICK, et al.	
				Group Art Unit	Not Yet Known	
	(use as many sh	eets as	necessary)	Examiner Name	Not Yet Known	
Sheet	3	of	5	Attorney Docket Number	DEAV2002/0087 - US - NP	

	U.S. PATENT DOCUMENTS								
		U.S. Paten	t Document		Date of Publication of	Pages, Columns, Lines,			
Examiner Initials*	Cite No. <sup>1</sup>	Number	Kind Code <sup>2</sup> ( <i>if known</i> )	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear			
	Ì								
	Ì								
					Î				
	- +		- +-+-						

				FOR	EIGN PATENT DOCUMENT	S		
Examiner Initials	Cite No.1	Office <sup>3</sup>	Foreign Patent Do	cument Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
		wo	02/068439		Kissei Pharmaceutical Co., Ltd	09-06-2002		
		wo	02/068440		Kissei Pharmaceuticals Co., Lt	09-06-2002		
		wo	02/080935		Ortho McNeil Pharmaceutical I	10-17-2002		
		wo	02/080936		Ortho McNeil Pharmaceutical I	10-17-2002		
		wo	02/28872		Kissei Pharmaceutical Co., Ltd	04-11-2002		
		wo	02/36602		Ajinomoto Co., Inc.	05-10-2002		
		wo	02/44192		Kissei Pharmaceutical Co., Ltd	06-06-2002		
	,	wo	03/020269		GLOMBIK	03-13-2003		
		wo	97/26265		Novo Nordisk A/S	07-24-1997		
		wo	97/41097		Dr. Reddy's Research Foundat	11-06-1997		

Examiner	Date	
Signature	Consider	red

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box ->	PTO/SB/08A (10-96) Approved for use through 10/31/99. OMB 0651-0031

	Patent and Trademan	k Office: U.S. DEPARTMENT OF COMMERC
Under the Paperwork Reduction Act of 1995	no persons are required to respond to a collection of information	unless it contains a valid OMB control number

Substitu	te for form 1449A/P	то		Complete if Known			
				Application Number	10/734,573		
INFO	DRMATIO	N DIS	SCLOSURE	Filing Date	12-12-2003		
STA	TEMENT	BY A	PPLICANT	First Named Inventor	FRICK, et al.		
				Group Art Unit	Not Yet Known		
	(use as many sh	ieets as	necessary)	Examiner Name	Not Yet Known		
Sheet	4	of	5	Attorney Docket Number	DEAV2002/0087 - US - NP		

				U.S. PATENT DOCU	JMENTS	
Examiner Initials	Cite No.1	U.S. Paten Number	Kind Code <sup>2</sup>	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
			$\longrightarrow$			
		,				
			1 1			

				FOR	EIGN PATENT DOCUMENT	ſS		
Examiner Initials*	Cite No.1	Office	Foreign Patent Do	cument Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		wo	98/08871		Novo Nordisk A/S	03-05-1998		
		wo	99/03861		Novo Nordisk A/S	01-28-1999		
		wo	99/15525		Sanofi	04-01-1999		$\square$
								╁
								$\perp$

Examiner		Date	
Signature		Considere	ed

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box 🛶	
lease type a plus sign (1) inside this box	

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitu	ite for form 1449B	/PTO		Complete if Known			
				Application Number	10/734,573		
INF	ORMATIC	I NC	DISCLOSURE	Filing Date	12-12-2003		
STATEMENT BY APPLICANT				First Named Inventor	FRICK, et al.		
			ALL EIGANT	Group Art Unit	Not Yet Known		
	(use as mai	ny shee	ts as necessary)	Examiner Name	Not Yet Known		
Sheet	5	of	5	Attorney Docket Number	DEAV2002/0087 - US - NP	$\supset$	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
		ASAKAWA A. et al., Cocaine-Amphetamine-Regulated Transcript Influences Energy Metabolism, Anxiety and Gastric Emptying in Mice, Hormone Metabolism Research, (2001), Vol. 33, pp. 554 - 558					
	:	LEE Daniel W. et al., Leptin agonists as a potential approach to the treatment of obesity, Drugs of the Future, (2001), Vol. 26, No. 9, pp. 873 - 881					
		OKADA Hiroshi et al., Synthesis and Antitumor Activities of Prodrugs of Benzoylphenylureas, Chemical Pharmaceutical Bulletin, (1994), Vol. 32, No. 1, pp. 57 - 61					
		SALVADOR Javier et al., Perspectives In The Therapeutic Use Of Leptin, Expert Opinion Pharmacotherapy, (2001), Vol. 2, No. 10, pp. 1615 - 1622					
	.,	TYLE Praveen, Iontophoretic Devices for Drug Delivery, Pharmaceutical Research, (1986), Vol. 3, No. 6, pp. 318 - 326					
		ZUNFIT H. J. F. et al., Carob Pulp Preparation for Treatment of Hypercholesterolemia, Advances In Therapy, (2001), Vol. 18, No. 5, pp. 230 - 236					
Examine	- - T	Date					

Examiner	Date	
Signature	Considered	_

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.